Atogepant open label data support long term efficacy and safety Sustained response to eptinezumab over 18 months Fresh insights on CGRP mAb and gepant prescribing New data support central action for fremanezumab and ubrogepant Zavegepant reduces need for analgesics AHS recommends anti-CGRP therapies as first line for migraine prevention Imaging data support central effects of erenumab Additive effects of multiple anti-CGRP therapies seen on CGRP-induced vasorelaxation

Galcanezumab

Galcanezumab

The CGRP monoclonal antibody, Emgality (galcanezumab), was approved for the prevention of migraine in adults in September 2018 and, in June 2019, became the first and only anti-CGRP therapy to be approved for the prevention of episodic cluster headache in adults. These approvals were supported by data including the results of the EVOLVE 1 and 2 trials in episodic migraine, the REGAIN trial in chronic migraine and a Phase 3 study in cluster headache. The CONQUER trial investigated the efficacy of galcanezumab in patients with migraine who had failed on 2-4 previous preventive therapies.

Download slideset »

« back to Slides

Educational Partners and Supporters

Lilly

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |